

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
24 July 2003 (24.07.2003)


PCT

(10) International Publication Number
WO 03/059945 A2

- (51) International Patent Classification⁷: **C07K 14/195**
- (21) International Application Number: **PCT/GB02/05941**
- (22) International Filing Date:
30 December 2002 (30.12.2002)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
0131026.7 28 December 2001 (28.12.2001) GB
0230247.9 28 December 2002 (28.12.2002) GB
- (71) Applicant (for all designated States except US): **FUSION ANTIBODIES LIMITED** [GB/GB]; P.O. Box 374, Belfast BT1 2WD (GB).
- (72) Inventors; and
(75) Inventors/Applicants (for US only): **MCKEOWN, Brendan** [GB/GB]; 15 Village Hill Mews, Straid, Ballyclare BT39 9WF (GB). **SCOTT, Christopher** [GB/GB]; 18 Cambrae Avenue, Belfast BT8 6NH (GB). **MCBRIDE, Alan** [GB/GB]; c/o 55 Warren Road, Donaghadee BT21 0PQ (GB). **BUICK, Richard** [GB/GB]; 24 Lisoom Road, Ballymena BT42 1AR (GB). **JOHNSTON, Jim** [GB/GB]; 18 Garland Avenue, Belfast BT8 6YH (GB).
- (74) Agent: **MURGITROYD & COMPANY**; Scotland House, 165-169 Scotland Street, Glasgow G5 8PL (GB).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,

[Continued on next page]

(54) Title: **SOLUBLE RECOMBINANT PROTEIN PRODUCTION**



(57) Abstract: Described is a method of producing a soluble bioactive domain of a protein, the method comprising the step of selecting suitable soluble subunits of a protein and assessing the produced protein for desired activity. The method may comprise the steps of amplifying DNA encoding at least one candidate soluble domain, cloning the amplified DNA into at least one expression vector, using each of said vectors into which the DNA has been cloned to each transfect or transform one or more host cell strains, expressing said DNA in one or more host cell strains, and analysing expression products from said host cells for solubility.

Each target insert is ligated into various vectors and transformed into hosts of *E. coli*. Typically, at least 3 inserts are designed for each target protein, each of which is ligated into 4 vectors on separate transformant plates. 24 clones from each transformant plate (i.e. total of 288 clones) are then propagated.



Flow chart of the fusion antibodies high-throughput process

WO 03/059945 A2



SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN,
YU, ZA, ZM, ZW.

Published:

— without international search report and to be republished
upon receipt of that report

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK,
TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*